Anticonvulsant activity of perampanel, a selective AMPA receptor antagonist, in rodent models of epileptic seizure

被引：0
|
作者：
Hashizume, Y. [1 ]
Hanada, T. [1 ]
Ogasawara, A. [1 ]
Ueno, M. [1 ]
Nishizawa, Y. [1 ]
机构：
[1] Eisai Tsukuba Res Labs, Tsukuba, Ibaraki, Japan
来源：
JOURNAL OF NEUROLOGY | 2008年 / 255卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O133
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [21] Perampanel, a Selective, Non-Competitive AMPA Receptor Antagonist, Prolongs Time to Seizure Recurrence in Patients with Epilepsy: Results of Pooled Phase III Clinical Trial Data
    Laurenza, Antonio
    French, Jacqueline
    Gil-Nagel, Antonio
    Guerrini, Renzo
    Squillacote, David
    Yang, Haichen
    Kumar, Dinesh
    NEUROLOGY, 2012, 78
  • [22] Perampanel, a Selective, Non-Competitive AMPA Receptor Antagonist, Prolongs Time to Seizure Recurrence in Patients with Epilepsy: Results of Pooled Phase III Clinical Trial Data
    Laurenza, Antonio
    French, Jacqueline
    Gil-Nagel, Antonio
    Guerrini, Renzo
    Squillacote, David
    Yang, Haichen
    Kumar, Dinesh
    NEUROLOGY, 2012, 78
  • [23] Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings
    Tsai, J. -J.
    Wu, T.
    Leung, H.
    Desudchit, T.
    Tiamkao, S.
    Lim, K. -S.
    Dash, A.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (04): : 378 - 391
  • [24] MULTIPLE-DOSE PHARMACOKINETIC STUDY OF PERAMPANEL, A NONCOMPETITIVE SELECTIVE AMPA RECEPTOR ANTAGONIST IN KOREAN HEALTHY SUBJECTS.
    Choi, H.
    Jung, J.
    Noh, Y-H
    Kim, D-J
    Parvez, M.
    Shin, J-G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S69 - S69
  • [25] Determination of Tolerability, Safety, and Efficacy of Perampanel, a Selective AMPA Receptor Antagonist, as Adjunctive Therapy in Subjects with Refractory Partial Seizures
    Krauss, Gregory L.
    Biton, Victor
    Klapper, Jack A.
    Bar, Michael
    Rektor, Ivan
    Vaiciene-Magistris, Nerija
    Skaringa, Algimantas
    Liigant, Aive
    Kumar, Dinesh
    Squillacote, David
    NEUROLOGY, 2009, 72 (11) : A442 - A442
  • [26] DETERMINATION OF TOLERABILITY, SAFETY, AND EFFICACY OF PERAMPANEL, A SELECTIVE AMPA RECEPTOR ANTAGONIST, AS ADJUNCTIVE THERAPY IN SUBJECTS WITH REFRACTORY PARTIAL SEIZURES
    Krauss, G.
    Biton, V.
    Klapper, J.
    Bar, M.
    Rektor, I.
    Vaiciene-Magistris, N.
    Liigant, A.
    Kumar, D.
    Squillacote, D.
    EPILEPSIA, 2009, 50 : 103 - 103
  • [27] THE NONCOMPETITIVE AMPA/KAINATE RECEPTOR ANTAGONIST, GYKI-52466, POTENTIATES THE ANTICONVULSANT ACTIVITY OF CONVENTIONAL ANTIEPILEPTICS
    BOROWICZ, KK
    GASIOR, M
    KLEINROK, Z
    CZUCZWAR, SJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 281 (03) : 319 - 326
  • [28] Oral AMPA-Receptor Antagonist from 12 Years Perampanel for focal Seizures
    Kretzschmar, Alexander
    NERVENHEILKUNDE, 2013, 32 (07) : 504 - 504
  • [29] Selective AMPA receptor antagonist GYKI 52466 is effective in three animal models of anxiety
    Kapus, G
    Gacsályi, I
    Vegh, M
    Lévay, G
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S362 - S362
  • [30] AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro
    Lange, Falko
    Wesslau, Konrad
    Porath, Katrin
    Hoernschemeyer, Julia
    Bergner, Carina
    Krause, Bernd Joachim
    Mullins, Christina Susanne
    Linnebacher, Michael
    Koehling, Ruediger
    Kirschstein, Timo
    PLOS ONE, 2019, 14 (02):
12345